CLOSTRIDIUM DIFFICILE EPIDEMIC OUTBREAK IN AN ONCOLOGY UNIT

Authors

  • L. MIRON Regional Institute of Oncology, Iasi
  • Raluca FILIMON Regional Institute of Oncology, Iasi
  • F. D. PETRARIU University of Medicine and Pharmacy "Grigore T. Popa" - Iasi
  • Mioara Calipsoana MATEI University of Medicine and Pharmacy "Grigore T. Popa" - Iasi

Keywords:

CLOSTRIDIUM DIFFICILE, NOSOCOMIAL INFECTION, ONCOLOGY, EPIDEMIC OUTBREAK.

Abstract

Aims: Contributions to the knowledge of some peculiarities of C. difficile involvement in human pathology, nosocomial infections (NI) included. Material and methods: This clinico-epidemiological and laboratory study included 14 patients admitted to the Medical Clinic of the Iasi Regional Cancer Institute with the diagnosis of C. difficile NI based on detection of toxins A and B in stool samples. The data were assessed and interpreted using an algorithm which revealed the peculiarities of C. difficile NI outbreak occurrence and evolution. Results: Of the 14 cases included in the study, 5 (35.8 %) had community-onset infections and 9 (64.3 %) oncology unit-onset infections. The average hospital stay was 22 days. Immunocompromised condition and the use of antibiotics in the ciprofloxacin, colistin and cefotaxime group for 4 - 10 days were the main risk factors. Conclusions: This epidemic C. difficile NI outbreak which affected immunocompromised patients with high susceptibility to infection, common finding in oncology care was brought under control by active preventive measures associated with concomitant antimicrobial therapy effective in C. difficile infections.

Author Biographies

  • L. MIRON, Regional Institute of Oncology, Iasi

    Internal Medicine of Oncology Clinic

  • Raluca FILIMON, Regional Institute of Oncology, Iasi

    Department of Nosocomial Infections Control and Prevention

  • F. D. PETRARIU, University of Medicine and Pharmacy "Grigore T. Popa" - Iasi

    Faculty of Medicine
    Discipline of Hygiene-Environmental Health

  • Mioara Calipsoana MATEI, University of Medicine and Pharmacy "Grigore T. Popa" - Iasi

    Faculty of Medicine
    Discipline of Primary Health Care and Epidemiology

References

1. Finegold SM. Anaerobic Bacteria in Human Disease, New York Academic Press; 1977.
2. Bartlett JG et al. Role of Clostridium difficile in antibiotic-associated pseudo membranous colitis. Gastroenterol. 1978; 75 (5): 778-782.
3. Bartlett JG et al. Antibiotic associated pseudo membranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298(10): 531-534.
4. Bartlett JG et al. Introduction. In: Role RD, Finegold SM (ed). Clostridium difficile: it’s role in intes-tinal diseases; San Diego, CA: Academic Press, Inc, 1988, 408-414.
5. Onderdonk AB, Garrett WS. Clostridium difficile – associated diseases (CDAD). In: Mandel, Bennett, Dolin (ed): Principles and Practice of Infectious Diseases; 7th ed., Churchill Livingstone, Elsevier, vol. 2, 2010, 3103-3109.
6. Asensio A et al. Increasing rates in Clostridium difficile infection (CDI) among hospitalized patients, Spain, 1977-2007. Euro Surveill 2008; 13 (31): 17-22.
7. Kuijper EJ et al. Update of Clostridium difficile infection due to PCR ribotype O27 in Europe, 2008. Euro Surveill 2008; 13 (31), 40-45.
8. Binion DG. Strategies for management of Clostridium difficile infection in immunosuppressed patients. Gastroenterol. Hepatol 2011; 7 (11): 750-752.
9. Zilberberg MD Clostridium difficile related hospitalization among US adults, 2006. Emerg Infect Dis 2009; 15 (11): 122-124.
10. Vonberg RP et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14 (suppl. S): 2-20.
11. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13 (9): 1417-1419.
12. Alcala I et al. Comparison of three commercial methods for the rapid detection of Clostridium difficile toxins A and B from faecal specimens. J Clin Microbiol 2008; 46 (11): 2833-2835.
13. Rusmann H et al. Evaluation of three rapid assays foe detection of Clostridium difficile toxin A and toxin B in stool specimens. Eur J Clin Microbiol Infect Dis 2007; 26 (2): 115-119.
14. Khan A, Raza S, Batul SA, Khan M, Aksoy T, Baig M, Berger BJ. The evaluation of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Pat Antiinfect Drug Discov 2012; 7 (2): 157-170.
15. Wysowski DK. Increase in death related to enterocolitis due to Clostridium difficile in the United States, 1999-2002. Public Health Rep 2006; 121 (4): 361-364.
16. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis 2013; 13 (11): 936-945.
17. Roberts K et al. Aerial dissemination of Clostridium difficile spores. BMC Infect Dis 2008; 8 (7): 11-15.
18. Byrn JC et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008; 143 (2): 150-154.

Additional Files

Published

2018-05-16

Issue

Section

PREVENTIVE MEDICINE - LABORATORY